Legend Biotech Announces Presentations at ASCO 2026
Legend Biotech announced multiple presentations at the ASCO 2026 meeting, including preliminary Phase 1 results for LB2102, a DLL3-targeted CAR-T therapy showing early activity in solid tumors like small cell lung cancer. Additional data on CARVYKTI (ciltacabtagene autoleucel) reinforces its efficacy in multiple myeloma, supporting ongoing studies …